Replimune Group (REPL) Projected to Post Quarterly Earnings on Thursday

Replimune Group (NASDAQ:REPL) is anticipated to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Replimune Group to post earnings of ($0.70) per share for the quarter.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts expect Replimune Group to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Replimune Group Price Performance

Replimune Group stock opened at $12.85 on Wednesday. The stock has a market cap of $879.20 million, a price-to-earnings ratio of -4.21 and a beta of 1.30. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The business has a 50-day simple moving average of $12.49 and a 200 day simple moving average of $11.64. Replimune Group has a 52 week low of $4.92 and a 52 week high of $17.00.

Wall Street Analyst Weigh In

Several research analysts have recently commented on REPL shares. HC Wainwright boosted their price objective on Replimune Group from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $19.14.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.